strateco



STRUCTURED FOR PROGRESS

HALF-YEAR FINANCIAL REPORT H1|2026

January 1 to June 30, 2026

MISSION STATEMENT

Together with our partners, we improve quality of life. We do this by leveraging our expertise, technology, and collaborative approach to develop innovative, purpose-built solutions for leading companies in in-vitro diagnostics and adjacent markets.

As a leading OEM partner, we share responsibility for the entire product life cycle: from initial design through development, regulatory approval, production, product expansion, and ongoing support.

Our success is based on the talent and dedication of our employees and our commitment to drive innovation forward.

CONTENTS

Current Information / Key Figures | **4**

Interim Group Management Report | **5**

Consolidated Balance Sheet as of June 30, 2026 | **12**

Consolidated Statement of Comprehensive Income
for the period from January 1 to June 30, 2026 | **14**

Consolidated Statement of Comprehensive Income
for the period from April 1 to June 30, 2026 | **15**

Consolidated Statement of Cash Flows
for the period from January 1 to June 30, 2026 | **16**

Consolidated Statement of Changes in Equity
for the period from January 1 to June 30, 2026 | **18**

Selected Explanatory Notes
for the period from January 1 to June 30, 2026 | **20**

Further Information | **32**

CURRENT INFORMATION

- Significantly more dynamic business performance in second quarter of 2026; as expected, year-on-year shortfall in sales and earnings reduced by end of H1/2026
- Consolidated sales in H1/2026 -3.3% at constant currency to € 112.5 million (H1/2025: € 118.6 million)
- Adjusted EBIT margin in H1/2026 almost matches previous year's figure thanks to significant upturn in profitability in second quarter of 2026 (adj. EBIT Q2/2026: +125.3%)
- Operating cash flow grows to € 29.7 million in H1/2026 (H1/2025: € -5.8 million)
- Ongoing high demand from customers for lifecycle management projects
- 2026 guidance confirmed: sales at constant currency expected to show growth in medium to high single-digit percentage range with adjusted EBIT margin at previous year's level (2025: 10.0%)

KEY FIGURES[I]

€ 000s	H1/2026	H1/2025	Change	Q2/2026	Q2/2025	Change
Sales	112,536	118,590	-5.1% (cc: -3.3%)	59,110	58,227	+1.5% (cc: +2.4%)
Adjusted EBITDA	15,691	16,070	-2.4%	10,999	6,765	+62.6%
Adjusted EBITDA margin (%)	13.9	13.6	+30 bps	18.6	11.6	+700 bps
Adjusted EBIT	7,731	8,487	-8.9%	7,039	3,124	+125.3%
Adjusted EBIT margin (%)	6.9	7.2	-30 bps	11.9	5.4	+650 bps
Adjusted consolidated net income	4,112	4,978	-17.4%	5,222	1,823	+186.5%
Adjusted earnings per share (€)	0.34	0.41	-17.1%	0.43	0.15	+186.7%
Earnings per share (€)	0.20	0.21	-4.8%	0.34	0.09	+277.8%

bps = basis points
cc = constant currency
[I] To facilitate comparison, figures have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and reorganisation expenses).

€ 000s	06.30.2026	12.31.2025	Change
Equity	238,438	237,320	+0.5%
Total assets	410,732	425,986	-3.6%
Equity ratio (%)	58.1	55.7	+240 bps

bps = basis points

INTERIM GROUP MANAGEMENT REPORT

Report on earnings, financial, and asset position

Earnings position

Consolidated sales of the STRATEC Group decreased by 3.3% at constant currency (nominal: -5.1%) to € 112.5 million in the first half of 2026 (H1/2025: € 118.6 million). In the second quarter of 2026, constant-currency sales grew by 2.4% compared with the previous year's quarter, thus making up for part of the shortfall in sales recorded at the beginning of the year.

Sales with Analyzer systems showed constant-currency growth of 15.4% (nominal: +13.7%) from € 34.9 million to € 39.7 million in the first half of 2026. The revival in demand already noticeable at the end of the past financial year continued in the second quarter of 2026, with particularly dynamic developments shown by call-up volumes in the fields of immunodiagnostics, molecular diagnostics, and immunohematology. By contrast, call-up volumes in the field of veterinary diagnostics and for products within the Diatron brand decreased due to an ongoing challenging climate in these submarkets.

Sales with Service Parts and Consumables showed a reduction at constant currency of 11.9% (nominal: -14.1%) to € 46.1 million, as against € 53.7 million in the first half of 2025. The sales performance here continued to be adversely affected by measures taken since the end of the past financial year at customers with amended ownership structures. These are manifestly intended to boost capital efficiency and achieve targeted optimizations in service costs and associated stock levels.

Given the previous year's high basis of comparison, sales at constant currency in the Development and Services business decreased by 7.8% (nominal: -9.0%) to € 26.2 million, compared with € 28.8 million in the first half of 2025.

Consolidated sales by operating division

€ 000s	H1/2026	H1/2025	Change
Analyzer systems	39,732	34,933	+13.7% cc +15.4%
Service Parts and Consumables	46,127	53,728	-14.1% cc -11.9%
Development and Services	26,161	28,750	-9.0% cc -7.8%
Other Activities	516	1,179	-56.2% cc -56.2%
Consolidated sales	**112,536**	**118,590**	**-5.1%** **cc -3.3%**

cc = constant currency

Gross profit (gross profit on sales) amounted to € 25.4 million in the first half of 2026, compared with € 32.0 million in the previous year's period. The associated gross margin for the first half of 2026 stood at 22.6% (H1/2025: 26.9%) and was adversely affected by, among other factors, sales mix and product mix factors.

At € 27.7 million in the first half of the 2026 financial year, investments in research and development (gross development expenses) fell slightly short of the previous year's figure of € 29.0 million. Of this total, € 3.2 million (H1/2025: € 5.4 million) involved expenses not meeting the criteria for capitalization pursuant to IAS 38 (Intangible Assets).

Sales-related expenses amounted to € 6.4 million in the first half of 2026 and thus approximated to the previous year's figure of € 6.5 million.

Given factors including lower personnel expenses, general administration expenses decreased year-on-year from € 13.0 million to € 12.0 million in the first half of 2026.

The net balance of income and expenses for impairments of financial assets and contract assets amounted to € -0.2 million in the first half of 2026 (H1/2025: € -0.4 million).

The net balance of other operating income and expenses stood at € 1.8 million in the first half of 2026 (H1/2025: € -1.3 million). Overall, this item benefited year-on-year from positive overall effects relating to the currency-related translation of balance sheet items.

Adjusted EBIT amounted to € 7.7 million in the first half of 2026, compared with € 8.5 million in the previous year's period. The adjusted EBIT margin stood at 6.9% and thus fell slightly short of the previous year's figure of 7.2%. The reduction in the margin in the first half of 2026 was principally attributable to negative effects of scale, as well as to sales mix and product mix effects. The margin benefited, by contrast, from ongoing consistent cost discipline and from currency translation effects, which have been recognized under other operating income and expenses.

The net financial result amounted to € -1.2 million in the first half of 2026, as against € -2.0 million in the previous year's period. The improvement in net financial expenses is chiefly attributable to the capitalization of borrowing costs.

Adjusted consolidated net income amounted to € 4.1 million in the first half of 2026, compared with € 5.0 million in the first half of 2025. On this basis, adjusted earnings per share stood at € 0.34 (H1/2025: € 0.41).

To facilitate comparison, the key earnings figures for the first half of 2026 have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and reorganisation expenses). A reconciliation of the adjusted figures with those reported in the consolidated statement of comprehensive income is presented in the following tables.

€ 000s	H1/2026	H1/2025
Adjusted EBITDA	**15,691**	**16,070**
Adjustments		
• Other[1]	-1,209	-1,551
EBITDA	**14,482**	**14,519**

[1] Including one-off advisory expenses, fees, and reorganisation expenses.

€ 000s	H1/2026	H1/2025
Adjusted EBIT	**7,731**	**8,487**
Adjustments		
• PPA amortization	-1,052	-1,617
• Other[1]	-1,209	-1,551
EBIT	**5,470**	**5,319**

[1] Including one-off advisory expenses, fees, and reorganisation expenses.

€ 000s	H1/2026	H1/2025
Adjusted consolidated net income	**4,112**	**4,978**
Adjusted earnings per share (basic)	**0.34**	**0.41**
Adjustments		
• PPA amortization	-1,052	-1,617
• Other[1]	-1,209	-1,551
• Taxes on income	598	792
Consolidated net income	**2,449**	**2,602**
Earnings per share in € (basic)	**0.20**	**0.21**

[1] Including one-off advisory expenses, fees, and reorganisation expenses.

Financial position

The cash flow from operating activities for the first half of 2026 amounted to € 29.7 million, compared with € -5.8 million in the previous year. This development was due in particular to a reduced volume of net working capital, as well as to significant year-on-year reduction in outgoing payments for income taxes.

At € 6.2 million, the outflow of funds for investing activities in the first six months of 2026 fell short of the previous year's figure of € 9.0 million. Of this total, € 3.5 million related to investments in intangible assets (H1/2025: € 3.9 million), while € 2.7 million involved investments in property, plant and equipment (H1/2025: € 5.1 million). The reduction in investments in property, plant and equipment relates in particular to the locations in Birkenfeld, Anif, and Ronkonkoma. The investment ratio (investments in property, plant and equipment and intangible assets as a percentage of sales) amounted to 5.5% in the first six months (H1/2025: 7.6%) and was therefore lower than the corridor of 6.5% to 8.5% planned for the 2026 financial year as a whole.

The cash flow from financing activities stood at € -27.4 million in the first half of 2026 (H1/2025: € -12.4 million) and comprised loan repayments amounting to € 18.3 million, the dividend of € 7.3 million distributed to shareholders in June 2026, and repayments of lease liabilities amounting to € 1.8 million.

Asset position

Total assets decreased to € 410.7 million as of June 30, 2026 (December 31, 2025: € 426.0 million).

Non-current assets amounted to € 212.9 million as of June 30, 2026 and were thus at almost the same level as at December 31, 2025 (€ 212.6 million). Changes arose in particular among intangible assets, with goodwill rising due to currency translation effects from € 49.9 million to € 52.1 million and other intangible assets from € 58.2 million to € 60.2 million. By contrast, property, plant and equipment declined from € 64.5 million to € 62.4 million.

Current assets decreased to € 197.8 million as of June 30, 2026 (December 31, 2025: € 213.4 million). This development was due above all to reductions in trade receivables from € 56.9 million to € 45.9 million and in cash from € 23.1 million to € 19.0 million. Inventories showed a slight increase from € 113.2 million to € 114.6 million.

On the equity and liabilities side of the balance sheet, trade payables increased from € 12.6 million as of December 31, 2025 to € 15.4 million as of June 30, 2026. By contrast, total current and non-current financial liabilities showed a marked reduction from € 135.5 million to € 115.7 million.

Shareholders' equity increased from € 237.3 million as of December 31, 2025 to € 238.4 million as of June 30, 2026. Due to the reduction in total assets, the equity ratio rose to 58.1% and was thus around 240 basis points higher than at December 31, 2025 (55.7%).

Macroeconomic and sector-specific framework

Macroeconomic framework[1]

In its Economic Outlook published in June 2026, the Organisation for Economic Cooperation and Development (OECD) warns of a substantial deterioration in global economic prospects. The conflict in the Middle East has triggered an energy shock that has resulted in higher energy and commodity prices, rising inflationary pressure, and weaker economic growth. Given the uncertainty surrounding future developments, the OECD has considered two scenarios.

In the time-limited disruption scenario, global growth is expected to slow from 3.4% in 2025 to 2.8% in 2026 and then recover to 3.1% in 2027. The US are expected to achieve growth of 2.0% in 2026 and 1.8% in 2027. Growth in the euro area is expected to stand at 0.8% in 2026 and rise to 1.2% in 2017. China is forecast to generate growth of 4.5% in 2026 and 4.3% in 2027.

Should the disruptions to energy production and exports in the Gulf States nevertheless last well into 2027 (prolonged disruption scenario), however, then global growth would weaken to 2.1% in 2026 and 1.8% in 2027. This scenario could lead to substantial supply shortages for energy and for agricultural and industrial upstream products, particularly in Asia, Europe, and the most affected developing economies, and thus have more prolonged negative impacts on production potential in these regions. In parallel, inflation would show a significantly greater increase than in the time-limited disruption scenario. The additional inflationary pressure compared with that scenario is estimated by the OECD as amounting to 0.4 percentage points in 2026 and 1.3 percentage points in 2027. In the more favorable scenario, inflation in the G20 economies is expected to rise from 3.4% in 2025 to 4.0% in 2026 and then decrease to 3.1% in 2027.

The OECD recommends central banks to remain alert. Price rises due to supply-side factors do not automatically require a monetary policy response as long as inflation expectations remain steady. Monetary policy measures may nevertheless be required in the event of a more broad-based intensification in price pressures or a marked weakness in growth. Government relief measures should be targeted at particularly affected households and small businesses, be limited in time, and continue to incentivize energy savings. In addition, countries should more clearly diversify their energy supply and enhance energy efficiency to reduce their vulnerability to future shocks.

The OECD also stresses the need to secure the long-term viability of government debt and strengthen the foundations for higher growth and greater productivity. Measures here include improving the business climate, boosting skills, and drawing on the potential offered by artificial intelligence and other transformative technologies. In particular, countries had to reduce their dependence on imported fossil fuels in the long term.

[1] Source: OECD: Economic Outlook, June 2026

Given its long-term project and product lifecycles, STRATEC and the decisions its customers take concerning joint development projects are only affected by macroeconomic fluctuations to a limited extent. Having said this, the macroeconomic climate is nevertheless a significant factor for STRATEC's business activity and is therefore factored extensively into the company's assessments and planning.

Sector-specific framework

Based on various estimates, the in-vitro diagnostics (IVD) market continues to show very healthy rates of sustainable growth and currently has a volume of around USD 100 billion.[1]

Consistently aging populations, the increased prevalence of chronic diseases, more frequent occurrence of infectious diseases, and the ever growing significance of more precise treatment (precision medicine) – these are key market growth drivers that are also sustainable. Over and above that, the research being performed on innovative technologies, such as specific biomarkers, will create new opportunities for future market growth.

Report on forecasts and other statements concerning the company's expected development

Demographic change and the increasing global prevalence of chronic and infectious diseases are creating ever-growing demand for in-vitro diagnostics test processes. In addition, precision medicine is further gaining in significance, as individualized therapeutic concepts require ever more precise and extensive diagnostic solutions. Furthermore, technological advances, particularly in terms of enhanced sensitivity and precision in in-vitro diagnostics systems, are providing access to new application fields, for example in oncology, neurology, and prenatal diagnostics. The existing shortage of qualified laboratory staff in many countries is additionally boosting demand for highly automated efficient system solutions. The trend towards outsourcing the design and manufacture of automation solutions to specialist partners such as STRATEC is also uninterrupted. Key drivers here include growing regulatory requirements and ever higher quality standards requiring extensive specialist expertise. At STRATEC, these developments are reflected both in the numerous market launches seen in recent years and in its well-filled development pipeline. The medium to long-term growth potential of the target markets addressed by the STRATEC Group and its customers are therefore assessed just as positively as ever.

The first-half sales and earnings performance confirmed the assumptions made in the company's intra-year planning for its 2026 financial guidance. As a result, and based on current orders and order forecasts received from customers, which are currently subject to highly elevated volatility, STRATEC's Board of Management can confirm the guidance provided for the 2026 financial year. STRATEC expects to generate year-on-year constant-currency consolidated sales growth in a medium to high single-digit percentage range in the 2026 financial year. The envisaged sales growth is expected to be generated almost exclusively from strong year-end business. The adjusted EBIT margin for 2026 is expected to approximate to the previous year's level (2025: 10.0%).

[1] Source: e.g. MarketsandMarkets: In Vitro Diagnostics Market, May 2025

For the 2026 financial year, STRATEC continues to budget for investments in property, plant and equipment and in intangible assets corresponding to a total of 6.5% to 8.5% of sales (2025: 6.5%).

To make optimal use of the wide variety of growth potential harbored by its current deal and development pipeline, STRATEC plans to maintain a stable workforce, or to expand this slightly, in the 2026 financial year.

STRATEC's financial guidance is based on budgets that account for and suitably weight both the specific features of its business model and numerous internal and external factors. Key factors in this respect include new orders, our customer's forecasts and their order behavior, their stocking of service parts, and the numbers of projects in development and negotiations. This guidance does not account for additional opportunities resulting from external growth (e.g. acquisitions). Given the long-term nature of its customer relationships, STRATEC only accords subordinate significance to macroeconomic fluctuations, meaning that this factor is only accounted for with a low weighting in the company's planning.

Opportunity and risk report

The risk management system forms an active part of STRATEC's corporate management and is largely based on three pillars. In the central early warning risk identification system, the risks facing the corporate divisions and the associated business environment are analyzed, evaluated, and monitored, with appropriate measures taken to counter such risks. Furthermore, the risk management system also comprises an internal control system (IKS) and a compliance management system, which additionally ensure compliance with relevant legal and industry-specific requirements.

Risk management covers all of the STRATEC Group's material operating and administrative departments.

The following principal changes arose as of June 30, 2026 compared with the risks listed in the Group Management Report for the 2025 financial year.

Macroeconomic and geopolitical uncertainties have further intensified as a result of the tensions surrounding the Persian Gulf. The scenarios referred to in the Economic Outlook published by the OECD in June 2026 range from a time-limited to a prolonged disruption in energy production and exports in the Gulf States. Depending on further developments, any prolonged disruption may lead to weaker global economic growth, rising energy and

commodity prices, and additional inflationary pressure. Prices, particularly for electronic storage media, may witness further upward pressure due to high demand for artificial intelligence applications. Storage media of this kind are also used, for example, in the PCs installed in analyzer systems. The resultant effects may impact directly on STRATEC's manufacturing and logistics costs and indirectly on demand and customers' willingness to invest. STRATEC is countering these developments where possible by maintaining stocks, diversifying its supplier base, and agreeing price adjustments with its customers. State-imposed export or supply restrictions, prolonged supply shortages, or price increases across the board may nevertheless impact on production security, the availability of critical components, and the development in the company's margins.

Although it remains important to stock high volumes of critical components, this may also lead to risks in the form of inventories that can no longer be used and increased capital commitment. As market demand recovers, the company therefore plans to significantly reduce its overall inventories and thus its working capital.

Given additional inflationary pressure and ongoing volatile and unpredictable developments in base rates, the company is reviewing the option of partly hedging those portions of its loans with floating interest rates.

Apart from the risks presented above, STRATEC currently does not see any further notable changes compared with the information provided in the Group Management Report on the 2025 financial year.

Details of our risk management system and our company's specific opportunity and risk profile and of our use of financial instruments can be found in the "Opportunities and Risks" section of the 2025 Group Management Report.

CONSOLIDATED BALANCE SHEET

as of June 30, 2026

Assets

€ 000s	06.30.2026	12.31.2025
Non-current assets		
Goodwill	52,104	49,853
Other intangible assets	60,219	58,157
Right-of-use assets	10,973	12,192
Property, plant and equipment	62,405	64,452
Non-current financial assets	4,117	4,085
Non-current other receivables and assets	254	294
Non-current contract assets	20,395	21,390
Deferred taxes	2,423	2,162
	212,890	**212,585**
Current assets		
Inventories	114,607	113,185
Trade receivables	45,905	56,933
Current financial assets	1,572	1,345
Current other receivables and assets	5,842	6,247
Current contract assets	9,126	8,228
Income tax receivables	1,757	4,407
Cash	19,033	23,056
	197,842	**213,401**
Total assets	**410,732**	**425,986**

Shareholders' equity and debt

€ 000s	06.30.2026	12.31.2025
Shareholders' equity		
Share capital	12,158	12,158
Capital reserve	37,598	37,498
Revenue reserves	184,887	189,732
Treasury stock	-35	-35
Other equity	3,830	-2,033
	238,438	**237,320**
Non-current debt		
Financial liabilities	100,164	110,653
Other liabilities	1,451	1,105
Contract liabilities	2,615	2,039
Provisions for pensions	4,067	4,158
Provisions	102	116
Deferred taxes	17,171	16,854
	125,570	**134,925**
Current debt		
Financial liabilities	15,556	24,862
Trade payables	15,394	12,635
Other liabilities	10,132	9,757
Contract liabilities	2,549	4,305
Provisions	405	461
Income tax liabilities	2,688	1,721
	46,724	**53,741**
Total shareholders' equity and debt	**410,732**	**425,986**

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the period from January 1 to June 30, 2026

€ 000s	01.01. – 06.30.2026	01.01. – 06.30.2025
Sales	112,536	118,590
Cost of sales	-87,096	-86,635
Gross profit	**25,440**	**31,955**
Research and development expenses	-3,205	-5,425
Sales-related expenses	-6,409	-6,507
General administration expenses	-12,049	-12,988
Income / Expenses from impairment of financial assets and contract assets	-153	-418
Other operating expenses	-2,413	-4,130
Other operating income	4,259	2,832
Earnings before interest and taxes (EBIT)	**5,470**	**5,319**
Financial income	89	121
Financial expenses	-1,281	-2,084
Other financial result	-4	-62
Net financial result	**-1,196**	**-2,025**
Earnings before taxes (EBT)	**4,274**	**3,294**
Taxes on income	-1,825	-692
Consolidated net income	**2,449**	**2,602**
Items that may be subsequently reclassified to profit or loss:		
Currency translation differences from translation of foreign operations	5,864	-1,548
Other comprehensive income (OCI)	**5,864**	**-1,548**
Comprehensive income	**8,313**	**1,054**
Basic earnings per share in €	**0.20**	**0.21**
No. of shares used as basis (undiluted)	12,155,942	12,155,942
Diluted earnings per share in €	**0.20**	**0.21**
No. of shares used as basis (diluted)	12,155,942	12,155,942

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the period from April 1 to June 30, 2026

€ 000s	01.04. – 06.30.2026	01.04. – 06.30.2025
Sales	59,110	58,227
Cost of sales	-43,871	-42,310
Gross profit	**15,239**	**15,917**
Research and development expenses	-1,487	-3,183
Sales-related expenses	-3,148	-3,152
General administration expenses	-6,488	-6,097
Income / Expenses from impairment of financial assets and contract assets	-50	-188
Other operating expenses	-1,201	-2,756
Other operating income	2,709	1,708
Earnings before interest and taxes (EBIT)	**5,574**	**2,249**
Financial income	55	56
Financial expenses	-260	-966
Other financial result	61	-1
Net financial result	**-144**	**-911**
Earnings before taxes (EBT)	**5,430**	**1,338**
Taxes on income	-1,268	-182
Consolidated net income	**4,162**	**1,156**
Items that may be subsequently reclassified to profit or loss:		
Currency translation differences from translation of foreign operations	4,777	-2,478
Other comprehensive income (OCI)	**4,777**	**-2,478**
Comprehensive income	**8,939**	**-1,322**
Basic earnings per share in €	**0.34**	**0.09**
No. of shares used as basis (undiluted)	12,155,942	12,155,942
Diluted earnings per share in €	**0.34**	**0.09**
No. of shares used as basis (diluted)	12,155,942	12,155,942

CONSOLIDATED STATEMENT OF CASH FLOWS

for the period from January 1 to June 30, 2026

€ 000s	01.01. – 06.30.2026	01.01. – 06.30.2025
I. Operations		
Consolidated net income (after taxes)	2,449	2,602
Depreciation and amortization	9,012	9,200
Current income tax expenses	1,768	1,208
Income taxes paid less income taxes received	1,763	-6,852
Financial income	-89	-121
Financial expenses	1,281	2,084
Interest paid	-1,280	-2,022
Interest received	72	167
Other non-cash expenses	1,542	3,650
Other non-cash income	-2,726	-1,869
Change in net pension provisions through profit or loss	-162	-219
Change in deferred taxes through profit or loss	57	-517
Profit (-) / loss (+) on disposals of non-current assets	-103	0
Increase (-) / decrease (+) in inventories, trade receivables and other assets	14,322	-7,432
Increase (+) / decrease (-) in trade payables and other liabilities	1,808	-5,650
Cash flow from operating activities	**29,714**	**-5,771**
II. Investments		
Incoming payments from disposals of non-current assets • Property, plant and equipment	8	0
Outgoing payments for investments in non-current assets • Intangible assets • Property, plant and equipment	 -3,480 -2,736	 -3,883 -5,077
Cash flow from investing activities	**-6,208**	**-8,960**
III. Financing		
Incoming funds from taking up of financial liabilities	0	21,429
Outgoing payments for repayment of financial liabilities	-18,342	-24,848
Outgoing payments for repayment of lease liabilities	-1,789	-1,700
Dividend payments	-7,294	-7,294
Cash flow from financing activities	**-27,425**	**-12,413**
IV. Cash-effective change in cash (net balance I – III)	**-3,919**	**-27,144**
Cash at start of period	23,056	47,164
Impact of exchange rate movements	-104	-1,322
Cash at end of period	**19,033**	**18,698**

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the period from January 1 to June 30, 2025

€ 000s	Share capital	Capital reserve	
December 31, 2024	**12,158**	**37,131**	
Equity transactions with owners			
• Dividend payment			
Allocations due to stock option programs		405	
Comprehensive income			
June 30, 2025	**12,158**	**37,536**	

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the period from January 1 to June 30, 2026

€ 000s	Share capital	Capital reserve	
December 31, 2025	**12,158**	**37,498**	
Equity transactions with owners			
• Dividend payment			
Allocations due to stock option programs		100	
Comprehensive income			
June 30, 2026	**12,158**	**37,598**	

	Other equity				
	Revenue reserves	Treasury stock	Pension plans	Currency translation	Group equity
	197,267	**-35**	**-1,521**	**-2,466**	**242,534**
	-7,294				**-7,294**
					405
	2,602			-1,548	**1,054**
	192,575	**-35**	**-1,521**	**-4,014**	**236,699**

	Other equity				
	Revenue reserves	Treasury stock	Pension plans	Currency translation	Group equity
	189,732	**-35**	**-638**	**-1,396**	**237,319**
	-7,294				**-7,294**
					100
	2,449			5,864	**8,313**
	184,887	**-35**	**-638**	**4,468**	**238,438**

SELECT EXPLANATORY NOTE DISCLOSURES

for the period from January 1 to June 30, 2026

Information about the company

STRATEC SE designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the STRATEC Group (hereinafter also "STRATEC") offers complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain – from development to design and production through to quality assurance. The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks, and research institutes around the world. STRATEC develops its products on the basis of its own technologies, most of which are patented. Customers gain access to these STRATEC technologies by purchasing products or acquiring licenses.

STRATEC SE is a stock corporation under European law (Societas Europaea – SE). In addition to the requirements of German stock corporation law, it is also subject to special European SE regulations, the German legislation governing the implementation of an SE (SE-Ausführungsgesetz), and the German legislation governing the participation of employees of an SE (SE-Beteiligungsgesetz). The company is registered with the number HRB 732007 in the Commercial Register at Mannheim District Court and has its legal domicile at Gewerbestrasse 37, 75217 Birkenfeld, Germany.

This Half-Year Financial Report was approved for publication by the Board of Management of STRATEC SE on August 14, 2026.

Basis of preparation

Consistent with § 115 (2) in conjunction with § 117 No. 2 of the German Securities Trading Act (WpHG), the Half-Year Financial Report prepared by STRATEC SE as the topmost parent company comprises interim consolidated financial statements, an interim group management report, and a responsibility statement. The interim consolidated financial statements, which have not been audited, have been prepared in abridged form in accordance with the requirements of IAS 34 (Interim Financial Reporting) and in accordance with those International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), London, and interpretations issued by the International Financial Reporting Interpretations Committee (IFRS IC) that were valid and endorsed by the EU as of the reporting date and, in the case of the interim group management report, additionally in accordance with the applicable requirements of the German Securities Trading Act (WpHG).

The interim consolidated financial statements have been prepared on the basis of historic cost with the exception of specific balance sheet line items which are measured at their fair values.

The interim consolidated financial statements have been prepared in accordance with the going concern principle and denominated in euros (€). Unless otherwise stated, all amounts are denominated in thousand euros (€ 000s). Due to numbers being rounded and presented in € 000s, individual figures in the consolidated financial statements of STRATEC SE may not add up exactly to the totals stated and percentage figures may not correlate exactly with the absolute figures to which they refer.

Accounting policies applied

Apart from those accounting standards and interpretations requiring mandatory application for the first time in the current financial year and unless indicated otherwise below, the accounting policies applied in the interim consolidated financial statements are consistent with those applied in preparing the consolidated financial statements as of December 31, 2025. A detailed description of the accounting policies was published in the notes to the consolidated financial statements. Reference is made to the information provided in Section "B. Accounting policies applied" in the 2025 Annual Report.

STRATEC has not made premature application of new or amended accounting standards and interpretations that have already been published but do not yet require mandatory application.

The following accounting standards and interpretations require mandatory application for the first time in the current financial year:

Standard	Title	Effective date[1]	EU endorsement
New and amended standards and interpretations			
Various	Amendments: Annual Improvements to IFRS Accounting Standards – Volume 11	01.01.2026	07.09.2025
IFRS 9, IFRS 7	Amendments: Classification of Financial Assets, Derecognition, Disclosures on Equity Instruments	01.01.2026	05.27.2025
IFRS 9, IFRS 7	Amendments relating to Contracts Referencing Nature-dependent Electricity	01.01.2026	06.30.2025

[1] For companies like STRATEC whose financial year corresponds to the calendar year

The application of these standards and interpretations in the current financial year is consistent with the respective transition requirements. Unless explicitly required by individual standards and interpretations and explained separately below, the respective requirements have generally been applied retrospectively, i.e. the information has been presented as if the new accounting methods had always been applied in the past. In these cases – and where called for by the respective standard – the comparative figures have been adjusted accordingly.

Impairment tests

STRATEC performs impairment tests pursuant to IAS 36 (Impairment of Assets) on goodwill and other intangible assets with unlimited or indefinite useful lives, as well as on intangible assets not yet ready for use, at least once a year. Furthermore, impairment tests pursuant to IAS 36 (Impairment of Assets) are performed when specific indications of impairment arise on the basis of external and internal sources of information.

Segment disclosures

STRATEC is a single-segment entity within the meaning of IFRS 8 (Operating Segments), as its business activities focus on the design and manufacture of automation solutions for partners in the field of in-vitro diagnostics. Internal reporting focuses on key value drivers such as technologies and systems related to these automation solutions. Accordingly, STRATEC is managed as a single reporting unit by its chief operating decision makers, who make decisions and allocate resources at this level.

The following is a summary of the key figures from the consolidated statement of consolidated income:

Summary of key figures from the consolidated statement of comprehensive income	01.01.–06.30.2026	01.01.–06.30.2025	Change
Sales (€ 000s)	112,536	118,590	-5.1% (cc: -3.3%)
Adjusted EBITDA (€ 000s)	15,691	16,070	-2.4%
Adjusted EBITDA margin (%)	13.9	13.6	+30 bps
Adjusted EBIT (€ 000s)	7,731	8,487	-8.9%
Adjusted EBIT margin (%)	6.9	7.2	-30 bps
Adjusted consolidated net income (€ 000s)	4,112	4,978	-17.4%
Adjusted earnings per share (€)	0.34	0.41	-17.1%
Earnings per share (€)	0.20	0.21	-4.8%

bps = basis points
cc = constant currency

To facilitate comparison, the key earnings figure have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and reorganisation expenses). The reconciliation of adjusted operating earnings before depreciation and amortization (EBITDA) with the earnings before taxes (EBT) reported in the consolidated statement of comprehensive income is as follows:

€ 000s	01.01.–06.30.2026	01.01.–06.30.2025
Adjusted operating earnings (EBIT)	**7,731**	**8,487**
PPA amortization	-1,052	-1,617
Advisory expenses and fees	-884	-1,185
One-off personnel expenses	-325	-366
Operating earnings (EBIT)	**5,470**	**5,319**
Net financial expenses	-1,196	-2,025
Earnings before taxes (EBT)	**4,274**	**3,294**

Scope of consolidation

In accordance with the requirements of IFRS 10 (Consolidated Financial Statements), the consolidated financial statements of STRATEC SE (parent company) basically include all companies controlled by STRATEC SE (subsidiaries). The scope of consolidation has not changed compared with December 31, 2025. Specifically, alongside STRATEC SE it comprises the following subsidiaries:

		Shareholding %	
Company	**Domicile**	**06.30.2026**	**12.31.2025**
Germany			
STRATEC Capital GmbH	Birkenfeld, Germany	100%	100%
STRATEC PS Holding GmbH	Birkenfeld, Germany	100%	100%
European Union			
STRATEC Biomedical S.R.L.	Cluj-Napoca, Romania	100%	100%
STRATEC Consumables GmbH	Anif, Austria	100%	100%
RE Medical Analyzers Luxembourg 2 S.à r.l.	Luxembourg, Luxembourg	100%	100%
Diatron Medicinai Instrumentumok Laboratóriumi Diagnosztikai Fejlesztö-Gyártó Zrt	Budapest, Hungary	100%	100%
Mod-n-More Kft.	Budapest, Hungary	100%	100%
Other			
STRATEC Switzerland AG	Beringen, Switzerland	100%	100%
STRATEC Biomedical USA, Inc.	Medley, USA	100%	100%
Medical Analyzers Holding GmbH	Zug, Switzerland	100%	100%
STRATEC Biomedical Inc.	Medley, USA	100%	100%
Diatron (US), Inc.	Medley, USA	100%	100%
Natech Plastics, Inc.	Ronkonkoma, USA	100%	100%
Diatron MI APAC Private Limited	Delhi, India	100%	100%
STRATEC Biomedical (Taicang) Co. Ltd., Taicang, China	Taicang, China	100%	100%
STRATEC Biomedical Ltd. Shanghai	Shanghai, China	100%	100%

Sales

The sales generated from contracts with customers are structured as follows:

€ 000s	01.01.–06.30.2026	01.01.–06.30.2025
Type of goods or services		
Analyzer systems	39,732	34,933
Service parts and consumables	46,127	53,728
Development and services	26,161	28,750
Other	516	1,179
Total	**112,536**	**118,590**
Geographical regions		
Germany	13,240	12,843
European Union	49,414	49,108
Other	49,882	56,639
• of which USA	40,882	49,696
Total	**112,536**	**118,590**
Time at which sales are recognized		
Recognized at a point in time	104,377	111,041
Recognized over time	8,159	7,549
Total	**112,536**	**118,590**

Research and development expenses

Research and development expenses not meeting the criteria for capitalization pursuant to IAS 38 (Intangible Assets) totaled € 3.2 million in the first six months of the 2026 financial year (previous year: € 5.4 million) and mainly involved personnel expenses and cost of materials. Overall, STRATEC invested a total of € 27.7 million in research and development in the first six months of the 2026 financial year (previous year: € 29.0 million).

Intangible assets, right-of-use assets, and property, plant and equipment

STRATEC invested a total of € 6,216k in intangible assets and property, plant and equipment in the first six months of the 2026 financial year (previous year: € 8,960k). This total includes borrowing costs of € 705k (previous year: € 0k) that have been capitalized as a component of cost pursuant to IAS 23 (Borrowing Costs).

Investments in intangible assets mainly relate to the capitalization of development expenses, while investments in property, plant and equipment chiefly involve the acquisition of building fittings, machinery, tools, and testing equipment.

Of intangible assets, € 39,526k (12.31.2025: € 38,873k) are located in the country of origin of STRATEC SE and € 72,797k (12.31.2025: € 69,139k) in third countries. The third countries with a material volume of intangible assets are Hungary (€ 33,021k; 12.31.2025: € 29,808k), the US (€ 25,394k; 12.31.2025: € 24,728k), and Austria (€ 12,295k; 12.31.2025: € 12,667k).

Of right-of-use assets, € 558k (12.31.2025: € 660k) are located in the country of origin of STRATEC SE and € 10,415k (12.31.2025: € 11,531k) in third countries. The third countries with a material volume of right-of-use assets are Hungary (€ 4,748k; 12.31.2025: € 5,013k), the US (€ 2,663k; 12.31.2025: € 2,866k), and Austria (€ 2,553k; 12.31.2025: € 3,200k).

Of property, plant and equipment, € 40,792k (12.31.2025: € 41,290k) are located in the country of origin of STRATEC SE and € 21,613k (12.31.2025: € 23,162k) in third countries. The third countries with a material volume of property, plant and equipment are Switzerland (€ 6,715k; 12.31.2025: € 6,926k), the US (€ 3,161k; 12.31.2025: € 3,871k), and Austria (€ 5,361k; 12.31.2025: € 6,037k).

Inventories

Inventories are structured as follows:

	06.30.2026 € 000s	12.31.2025 € 000s
Raw materials and supplies	89,896	92,480
Unfinished products	8,546	7,461
Finished products	12,369	8,816
Merchandise	968	743
Prepayments made	2,828	3,685
Total	**114,607**	**113,185**

Financial instruments

The table below presents the carrying amounts for each individual measurement category and the fair values for each individual measurement class of financial instruments pursuant to IFRS 9 (Financial Instruments) and reconciles these with the respective balance sheet items. No offsetting was performed within the financial line items as of the balance sheet date, neither was there any netting potential.

Abbreviations for measurement categories:

AC	Measured at (amortized) cost
FVTPL	Measured at fair value through profit or loss
FVTOCI	Measured at fair value through other comprehensive income (OCI)
n/a	Not attributable to any measurement category

06.30.2026 (12.31.2025)	IFRS 9 category	Carrying amount € 000s	Amortized cost € 000s	Fair value of which Level 1 € 000s	Fair value of which Level 2 € 000s	Fair value of which Level 3 € 000s	Not attributable to any measurement category € 000s	Total € 000s
Non-current assets								
Financial assets								
• Amortized cost	AC	3,537 (3,505)	3,537 (3,505)					3,537 (3,505)
• Fair value through OCI	FVTOCI	580 (580)				580 (580)		580 (580)
Current assets								
Trade receivables	AC	45,905 (56,933)	45,905 (56,933)					45,905 (56,933)
Financial assets								
• Amortized cost	AC	1,072 (842)	1,072 (842)					1,072 (842)
• Fair value through profit or loss	FVTPL	500 (503)		500 (503)				500 (503)
Cash	AC	19,033 (23,056)	19,033 (23,056)					19,033 (23,056)
Total financial assets by category								
of which amortized cost	AC		69,547 (84,336)	0 (0)	0 (0)	0 (0)		69,547 (84,336)
of which fair value through profit or loss	FVTPL		0 (0)	500 (503)	0 (0)	0 (0)		500 (503)
of which fair value through OCI	FVTOCI		0 (0)	0 (0)	0 (0)	580 (580)		580 (580)
Non-current debt								
Financial liabilities								
• Amortized cost	AC	100,164 (110,653)	92,828 (101,758)				7,336 (8,895)	100,164 (110,653)
Current debt								
Financial liabilities								
• Amortized cost	AC	15,361 (24,825)	11,790 (21,270)				3,571 (3,555)	15,361 (24,825)
• Fair value through profit or loss	FVTPL	195 (37)			195 (37)			195 (37)
Trade payables	AC	15,394 (12,635)	15,394 (12,635)					15,394 (12,635)
Total financial debt by category								
of which amortized cost	AC		120,012 (135,663)	0 (0)	0 (0)	0 (0)		120,012 (135,663)
of which fair value through profit or loss	FVTPL		0 (0)	0 (0)	195 (37)	0 (0)		195 (37)

Fair value hierarchy

As in the comparative period for the previous year, no items were reclassified within the three input factor levels in the first six months of the 2026 financial year. Any reclassifications into or out of fair value hierarchy levels are performed at the end of the reporting period.

The financial assets allocated to Level 1 involve shares in listed companies, which have been measured at the closing price on the stock market with the highest trading volumes as of the interim balance sheet date. The financial assets and liabilities allocated to Level 2 involve forward exchange transactions to hedge currency risks. The financial assets allocated to Level 3 involve shares in unlisted companies, for which the fair value has been determined by reference to non-observable input factors.

The fair value of financial instruments is determined as the present value of future cash inflows or outflows. Discounting is based on a market interest rate with a congruent term and risk structure. For financial instruments measured at fair value, a quoted price in an active market is used, if available. For short-term financial assets and liabilities not measured at fair value, the fair values approximate to their carrying amounts due to the short remaining terms. For non-current other financial assets measured at amortized cost, the carrying amount also approximates to fair value due to deposits with banks and the correspondingly very low credit risk. The fair value of non-current financial liabilities measured at amortized cost amounts to € 89,064k (12.31.2025: € 97,331k) and is allocated to Level 3.

Financial liabilities

Financial liabilities include liabilities to banks of € 101,280k (12.31.2025: € 119,681k) and lease liabilities of € 10,907k (12.31.2025: € 12,450k).

Liabilities to banks include liabilities of € 82.0 million (12.31.2025: € 92.5 million) in connection with a syndicated loan agreement which was concluded by STRATEC SE on August 27, 2025 and has a term through to August 27, 2030. This has the possibility of being extended twice by one year in each case if certain conditions are met and at specific dates.

The syndicated loan agreement has a credit volume of € 125.0 million and has the option of being increased by between a minimum of € 10.0 million and a maximum of € 40.0 million. The credit volume is divided into two facilities. With a volume of € 75.0 million, Facility A is an amortizing loan facility which provides for fixed repayments of € 3.0 million as of March 31 and September 30 respectively, with the first such repayment due on March 31, 2026. This facility serves in particular to refinance amounts drawn down from existing master credit agreements. Facility A has been fully drawn on in an amount of € 75.0 million. By contrast, Facility B, which has a volume of € 50.0 million, plus the option of being increased, is a revolving credit line which may be used both for general company management purposes and for acquisitions. It therefore provides STRATEC with sufficient flexibility for the future. Of Facility B, an amount of € 10.0 million had been drawn down as of June 30, 2026 (12.31.2025: € 17.5 million), with € 10.0 million of this amount recognized under non-current financial liabilities (12.31.2025: € 13.0 million). To the extent that they relate to Facility A, the transaction costs associated with the syndicated loan agreement are amortized using the effective interest method. The carrying amount of Facility A stood at € 72.4 million as of June 30, 2026 (12.31.2025: € 75.4 million).

The interest payable on amounts drawn down from Facilities A and B is calculated based on the EURIBOR for an interest period, plus a margin based on the company's net debt ratio. Non-compliance with the net debt ratio leads to the margin being increased by a premium. The interest periods for Facility A may amount to three or six months, while those for Facility B may amount to one, three, or six months. Unutilized credit amounts are subject to a provision fee.

Premature termination of the credit agreement by the lenders is permitted if the borrower fails to comply with its contractual obligations or its duty to provide information, taking due account of the possibility granted in some cases to the borrower to remedy such failure. The lender may voluntarily terminate an available facility, taking due account of a minimum amount of € 5 million and assuming compliance with a notice period of five banking days. All repayments made prior to the end of a given interest period are subject to an obligation to pay a prepayment penalty.

In addition to the syndicated loan agreement, the company had further liabilities to banks as of June 30, 2026. Excluding accrued interest, these amounted to € 18.9 million (12.31.2025: € 26.6 million) and resulted from various loan agreements with different terms.

For the predominant share of financial liabilities to banks, the respective financing agreements include agreements concerning compliance with specific key financial figures (covenants). These covenants must be calculated as of the end of each quarter, half year, and full year and must be communicated to the lending banks. Furthermore, STRATEC is also subject to extensive certification, informational, and reporting obligations, such as the obligation to submit audited separate and consolidated financial statements by April 30 each year. Non-compliance with the aforementioned covenants or the informational and reporting obligations entitles the banks to terminate the respective facilities. Consistent with the arrangements applicable at the respective reporting date, the company met its reporting obligations and complied with the financial covenants in the first six months of the 2026 financial year.

Other liabilities

Other liabilities include the total obligation of € 220k (12.31.2025: € 246k) stated for expected payments in connection with the stock appreciation rights (SARs) granted. In the first six months of the 2026 financial year, income of € 26k was recognized through profit or loss for cash-settled share-based payments (previous year: expenses of € 79k).

The fair value of stock appreciation rights (SARs) developed as follows:

Stock appreciation rights (SARs): Model parameters	**Tranche 1/2026**	**Tranche 1/2025**	**Tranche 1/2024**	**Tranche 1/2023**	**Tranche 1/2022**
Issue date	01.26.2026	02.10.2025	01.19.2024	01.23.2023	01.25.2022
Average share price on issue date	€ 23.35	€ 34.85	€ 40.50	€ 84.70	€ 114.40
Term					
• Overall term	84.0 months	84.0 months	84.0 months	84.0 months	60.0 months
• Remaining term as of 06.30.	78.9 months	67.4 months	54.7 months	42.8 months	6.9 months
• Model terms	28.4 months 54.0 months 78.9 months	28.4 months 54.0 months	28.4 months 54.0 months	28.4 months 42.8 months	6.9 months
Minimum waiting period					
• Overall term	48.0 months	48.0 months	48.0 months	48.0 months	24.0 months
• Remaining term as of 06.30.	42.9 months	31.4 months	18.7 months	6.8 months	0,.0 months
Share price at measurement date	€ 16.80	€ 16.80	€ 16.80	€ 16.80	€ 16.80
Fair value on issue date	**€ 6.45**	**€ 10.58**	**€ 12.60**	**€ 31.35**	**€ 37.45**
Fair value as of 06.30.2026	**€ 2.62**	**€ 1.18**	**€ 1.17**	**€ 0.09**	**€ 0.00**

The development in the number of stock appreciation rights (SARs) is presented below:

Number of rights	Total at 01.01.2026	Granted	Exercised / lapsed / forfeited	Total at 06.30.2026	of which exercisable
Tranche 1/2021	22,500	0	-22,500	0	0
Tranche 1/2022	22,500	0	0	22,500	0
Tranche 1/2023	38,370	0	0	38,370	0
Tranche 1/2024	40,340	0	0	40,340	0
Tranche 1/2025	41,000	0	0	41,000	0
Tranche 1/2026	0	46,000	0	46,000	0
Total	**164,710**	46,000	**-22,500**	**188,210**	**0**

Risk management activities

STRATEC's assets, liabilities, and future activities are subject to liquidity risks, default risks, and market risks resulting from changes in exchange rates, interest rates, and stock market prices.

The gross carrying amounts of trade receivables by time band and the allowances stated for "expected credit losses" are structured as follows:

			of which: overdue at balance sheet date within following time bands		
€ 000s	Gross amount	of which: not overdue at balance sheet date	up to 30 days	between 30 and 90 days	more than 90 days
06.30.2026	49,069	36,823	6,153	1,490	4,603
Expected credit loss		165		156	2,842
12.31.2025	59,948	48,018	7,103	1,721	3,106
Expected credit loss		266		262	2,487

STRATEC had concluded hedging transactions as of June 30, 2026. These involve currency futures intended to hedge future cash flows from sales in USD. No use was made of the hedge accounting provisions of IFRS 9 (Financial Instruments).

Shareholders' equity

The development in shareholders' equity at STRATEC and dividends paid is presented in the consolidated statement of changes in equity. The number of ordinary shares issued by STRATEC SE as of June 30, 2026 amounts to 12,157,841 (previous year: 12,157,841; 12.31.2025: 12,157,841). All shares are fully paid in and are registered shares.

Treasury stock holdings

The company owned 1,899 treasury stock shares as of June 30, 2026 (12.31.2025: 1,899). This corresponds to a prorated amount of € 1,899.00 of the company's share capital and to a 0.02% share of its equity (12.31.2025: 0.02%).

Stock option programs

The company had two (previous year: three) stock option programs (equity-settled share-based payment) as of June 30, 2026.

The following options schedule provides a summary of the development in stock option rights in the period under report:

Stock option rights	Board of Management No. of options	Employees No. of options	Total No. of options
Outstanding on 01.01.2026	**29,557**	**190,525**	**220,082**
• of which exercisable	0	0	0
Granted	0	5,500	5,500
Exercised	0	0	0
Lapsed	7,500	1,500	9,000
Forfeited	0	11,000	11,000
Outstanding on 06.30.2026	**22,057**	**183,525**	**205,582**
• of which exercisable	0	0	0

Components of other comprehensive income

The other equity of € 3,830k (previous year: € -5,536k; 12.31.2025: € -2,033k) includes the currency translation reserve, cumulative actuarial gains and losses from the remeasurement of pensions, and the resultant deferred taxes.

The currency translation reserve of € 4,468k recognized as of June 30, 2026 (previous year: € -4,014k; 12.31.2025: € -1,396k) mainly comprises currency differences arising upon the translation of the separate financial statements of companies whose functional currency is not the euro and from the translation within equity of group-internal net investments as of the reporting date. The change in this item is recognized in the "Currency translation differences from translation of foreign business operations" line item in the consolidated statement of comprehensive income.

Select related party disclosures

In addition to the companies included in the interim consolidated financial statements, STRATEC SE has relationships with related companies and individuals (related parties). These include business relationships with members of the Supervisory Board and Board of Management of STRATEC SE and their close relatives.

In the context of an employment relationship, STRATEC procured services of € 93k from a close family relation of a member of the Board of Management in the first six months of 2026 financial year (previous year: € 87k). As of June 30, 2026, balances of € 67k were outstanding in connection with the employment relationship (12.31.2025: € 49k).

As of June 30, 2026, STRATEC reported outstanding balances due to members of the Board of Management. These amounted to € 1,735k in connection with profit participation (12.31.2025: € 1,798k) and to € 3,385k in connection with the company pension scheme (12.31.2025: € 3,139k).

As of June 30, 2026, STRATEC reported outstanding balances of € 160k due to members of the Supervisory Board in connection with their activities in the Supervisory Board, in the Audit Committee, and in the Remuneration Committee (12.31.2025: € 300k).

Employees

Including temporary employees and trainees, STRATEC had a total of 1,383 employees as of June 30, 2026 (previous year: 1,416; 12.31.2025: 1,403).

Major events after the interim balance sheet date

No events of particular significance which can be expected to materially influence the Group's earnings, financial, or asset position have occurred since the interim balance sheet date.

Responsibility statement

We hereby affirm that, to the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group consistent with the principles of proper accounting, and the interim group management report includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group in the remainder of the financial year.

Birkenfeld, August 14, 2026

STRATEC SE

The Board of Management

Marcus Wolfinger

Dr. Claus Vielsack

Dr. Georg Bauer

Tanja Bücherl

FINANCIAL CALENDAR

08	11	11
08.14.2026	**11.12.2026**	**11.24.2026**
Half-year Financial Report H1|2026	Quarterly Statement 9M|2026	German Equity Forum (Analyst Conference)

Subject to amendment.
Quarterly statements and half-year financial reports are neither audited nor subject to an audit review by the group auditor.

ABOUT STRATEC

STRATEC SE (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and life sciences. Furthermore, the company offers complex consumables for diagnostic and medical applications. For its analyzer systems and consumables, STRATEC covers the entire value chain – from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange.

IMPRINT AND CONTACT

Published by
STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 7082 7916-0
info@stratec.com
www.stratec.com

Head of Investor Relations,
Sustainability & Corporate Communications
Jan Keppeler
Phone: +49 7082 7916-6515
j.keppeler@stratec.com

Notice
Forward-looking statements involve risks: This half-year financial report contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

This half-year financial report contains various disclosures that from an economic point of view are not required by the relevant accounting standards. These disclosures should be regarded as a supplement, rather than a substitute for the IFRS disclosures.

Apparent discrepancies may arise throughout this half-year financial report on account of mathematical rounding up or down in the course of addition.

This half-year financial report is available in both German and English. Both versions can be downloaded from the company's website at www.stratec.com. In the event of any discrepancies between the two, the German report is the definitive version.